The dividend of traditional biochemical technology in the medical field seems to have come to an end.

At present, the research and development cost of a new drug is about 2.6 billion US dollars, which takes about 10 years. However, the success rate of the drug approved for marketing (LOA) in the clinical trial stage is less than 10%, especially the tumor drug is only 5.1%. This means that many new tumor drug R&D projects cannot escape the fate of being eliminated.

In view of this, both the government's planning documents and the frequent actions of investment and financing institutions and pharmaceutical enterprises place their hopes on the enabling of information technology for the innovation of the pharmaceutical industry.

Phil Rivers proposed the concept of computational medicine. T Computational medicine takes system theory as the guiding ideology, adopts intensive data driven research paradigm, artificial intelligence as the method, high-performance computing as the support, and contributes new insights and solutions to the whole chain industry in the biomedical field through the dual wheel drive of knowledge model and data model.

Recently, Phil Rivers announced that it had completed round A financing of nearly 100 million yuan. Phil Rivers focuses on drug research and development driven by "AI+disease" to solve the problem of unclear pathogenesis, which is the core problem of drug innovation. It is reported that it has built two AI tool platforms - new target and new mechanism delivery platform and virtual clinical trial platform, pointing to six application scenarios: new target, new mechanism, new biomarker, design of clinical trial scheme, prediction of clinical trial results, and expansion of new indications.

Source: Guangming Daily APP